Abstract
Alzheimers disease (AD) is a progressive, neurodegenerative disorder that results in severe cognitive decline. Amyloid plaques are a principal pathology found in AD and are composed of aggregated amyloid- beta (Aβ) peptides. According to the amyloid hypothesis, Aβ peptides initiate the other pathologies characteristic for AD including cognitive deficits. Immunotherapy against Aβ is a potential therapeutic for the treatment of humans with AD. While anti-Aβ immunotherapy has been shown to reduce amyloid burden in both mouse models and in humans, immunotherapy also exacerbates vascular pathologies. Cerebral amyloid angiopathy (CAA), that is, the accumulation of amyloid in the cerebrovasculature, is increased with immunotherapy in humans with AD and in mouse models of amyloid deposition. CAA persists in the brains of clinical trial patients that show removal of parenchymal amyloid. Mouse model studies also show that immunotherapy results in multiple small bleeds in the brain, termed microhemorrhages. The neurovascular unit is a term used to describe the cerebrovasculature and its associated cells-astrocytes, neurons, pericytes and microglia. CAA affects brain perfusion and there is now evidence that the neurovascular unit is affected in AD when CAA is present. Understanding the type of damage to the neurovascular unit caused by CAA in AD and the underlying cause of microhemorrhage after immunotherapy is essential to the success of therapeutic vaccines as a treatment for AD.
Keywords: Immunotherapy, Microhemorrhages, Vascular Pathology, Transgenic Mice, Aβ peptides, amyloid hypothesis
CNS & Neurological Disorders - Drug Targets
Title: Immunotherapy, Vascular Pathology, and Microhemorrhages in Transgenic Mice
Volume: 8 Issue: 1
Author(s): Donna M. Wilcock and Carol A. Colton
Affiliation:
Keywords: Immunotherapy, Microhemorrhages, Vascular Pathology, Transgenic Mice, Aβ peptides, amyloid hypothesis
Abstract: Alzheimers disease (AD) is a progressive, neurodegenerative disorder that results in severe cognitive decline. Amyloid plaques are a principal pathology found in AD and are composed of aggregated amyloid- beta (Aβ) peptides. According to the amyloid hypothesis, Aβ peptides initiate the other pathologies characteristic for AD including cognitive deficits. Immunotherapy against Aβ is a potential therapeutic for the treatment of humans with AD. While anti-Aβ immunotherapy has been shown to reduce amyloid burden in both mouse models and in humans, immunotherapy also exacerbates vascular pathologies. Cerebral amyloid angiopathy (CAA), that is, the accumulation of amyloid in the cerebrovasculature, is increased with immunotherapy in humans with AD and in mouse models of amyloid deposition. CAA persists in the brains of clinical trial patients that show removal of parenchymal amyloid. Mouse model studies also show that immunotherapy results in multiple small bleeds in the brain, termed microhemorrhages. The neurovascular unit is a term used to describe the cerebrovasculature and its associated cells-astrocytes, neurons, pericytes and microglia. CAA affects brain perfusion and there is now evidence that the neurovascular unit is affected in AD when CAA is present. Understanding the type of damage to the neurovascular unit caused by CAA in AD and the underlying cause of microhemorrhage after immunotherapy is essential to the success of therapeutic vaccines as a treatment for AD.
Export Options
About this article
Cite this article as:
Wilcock M. Donna and Colton A. Carol, Immunotherapy, Vascular Pathology, and Microhemorrhages in Transgenic Mice, CNS & Neurological Disorders - Drug Targets 2009; 8 (1) . https://dx.doi.org/10.2174/187152709787601858
DOI https://dx.doi.org/10.2174/187152709787601858 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cerebrospinal Fluid Proteomes: From Neural Development to Neurodegenerative Diseases
Current Proteomics Etiopathogenesis, Classical Immunotherapy and Innovative Nanotherapeutics for Inflammatory Neurological Disorders
Current Nanoscience Alcohol Drinking, Apolipoprotein Polymorphisms and the Risk of Cardiovascular Diseases
Current Neurovascular Research Peripheral Chemo-Cytokine Profiles in Alzheimers and Parkinsons Diseases
Mini-Reviews in Medicinal Chemistry Insights into the Design of p97-targeting Small Molecules from Structural Studies on p97 Functional Mechanism
Current Medicinal Chemistry The Use of Stem Cells for the Treatment of Spinal Surgical Conditions.
Current Stem Cell Research & Therapy New Strategies for the Synthesis of Bio-medically Relevant Oligosaccharides: Recent Updates on 1,2-cis-O-Glycosylation and α-O-Sialylation
Current Organic Synthesis Nicotinic Receptors Containing the α7 Subunit: A Model for Rational Drug Design
Current Medicinal Chemistry Modulation of the Ceramide Level, A Novel Therapeutic Concept
Current Drug Targets Low Density Lipoprotein Receptor-Related Proteins (LRPs), Alzheimers and Cognition
Current Drug Targets - CNS & Neurological Disorders Role of Nicotinic Acetylcholine Receptors in Cardiovascular Physiology and Pathophysiology: Current Trends and Perspectives
Current Vascular Pharmacology Spatial Correlations between the Vacuolation, Prion Protein (PrPsc) Deposits and the Cerebral Blood Vessels in Sporadic Creutzfeldt-Jakob Disease
Current Neurovascular Research Mitochondria-Targeted Antioxidant Peptides
Current Pharmaceutical Design ADAM Proteases: Protective Role in Alzheimers and Prion Diseases ?
Current Alzheimer Research NADPH Oxidase and Neurodegeneration
Current Neuropharmacology Neurodegenerative Pathways in Alzheimer’s Disease: A Review
Current Neuropharmacology Mesenchymal Stem Cells of Dental Origin-Their Potential for Antiinflammatory and Regenerative Actions in Brain and Gut Damage
Current Neuropharmacology Targeting Mitochondria in Fighting Cancer
Current Pharmaceutical Design Gabapentin-Mediated Effects on Voltage- and Ligand-Gated Currents
Current Neuropharmacology Management of Glia-Mediated Neuroinflammation and Related Patents
Recent Patents on Inflammation & Allergy Drug Discovery